ReviewNeuroscience and biobehavioral reviews2026
The neuroimmune-glutamate hypothesis of addiction.
Review in Neuroscience and biobehavioral reviews, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Addictive drugs impact corticostriatal glutamate signaling and have immunomodulatory effects which may underlie drug-associated behaviors during different phases of the addiction cycle. Here we hypothesize that glutamate dyshomeostasis induced by addictive drug use and withdrawal is heavily orchestrated by the neuroimmune system. We systematically define how drug-induced pathologies within the nucleus accumbens (NA) glutamate tripartite synapse are tightly regulated by neuroimmune signaling. Targets within the neuroimmune system represent a novel approach that can be leveraged for clinical studies with immunomodulatory therapeutics to reverse neurobiological changes induced by addictive drugs, and thus meaningfully reduce negative clinical outcomes relevant to substance use disorders (SUDs). We outline a novel hypothesis that control of a newly defined neuroimmune-glutamate circuit and inflammasome is heavily dependent upon the type of addictive drug as well as on phase of the addiction cycle. We further provide translational evidence underscoring the tenet that neuroimmunomodulation by addictive drugs functions according to an opponent process, and we outline predictions of our opponent process hypothesis when applied to relevant polysubstance use patterns in people who use drugs. This framework could be strategically leveraged in the experimental design of clinical studies of novel SUD therapeutics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.